Cephalon’s Fentora AC Review To Weigh Necessity Of Opioid Use For Pain Against Potential For Misuse
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm proposes tighter risk management plan for a non-cancer breakthrough pain indication.
You may also be interested in...
Panel COVERS Problems With Cephalon’s Fentora
Risk-management plan is “impressive,” but needs supporting evidence, FDA advisors say.
Panel COVERS Problems With Cephalon’s Fentora
Risk-management plan is “impressive,” but needs supporting evidence, FDA advisors say.
Purdue’s OxyContin Tablets AC Review To Focus On Risk Management Strategies
Reformulation has more abuse-deterrent physical properties, firm says.